- Senexin A
-
- $31.00 / 1mg
-
2025-11-10
- CAS:1366002-50-7
- Min. Order:
- Purity: 98.00%
- Supply Ability: 10g
|
| | Senexin A Basic information |
| Product Name: | Senexin A | | Synonyms: | Senexin A;4-(Phenethylamino)quinazoline-6-carbonitrile;6-Quinazolinecarbonitrile, 4-[(2-phenylethyl)amino]-;Senexin A (This product is unavailable in the U.S.);4-[(2-Phenylethyl)amino]-6-quinazolinecarbonitrile;Cyclin dependent kinase,Senexin A,Inhibitor,CDK,inhibit;Senexin A, 10 mM in DMSO | | CAS: | 1366002-50-7 | | MF: | C17H14N4 | | MW: | 274.32 | | EINECS: | | | Product Categories: | | | Mol File: | 1366002-50-7.mol |  |
| | Senexin A Chemical Properties |
| Boiling point | 520.0±45.0 °C(Predicted) | | density | 1.24±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: ≥ 100 mg/mL (364.54 mM) | | form | Powder | | pka | 6.47±0.50(Predicted) | | color | White to off-white |
| | Senexin A Usage And Synthesis |
| Uses | Senexin A is a useful intermediate. | | in vivo | Five daily treatment of Senexin A fully reverses tumor-promoting effect of chemotherapy. Senexin A shows no detectable toxicity and no significant effects on body weight, organ weights, or blood cell counts in C57BL/6 mice during the treatment. This effect of doxorubicin treatment is completely abolished, however, when doxorubicin injection is followed by administration of Senexin A. Senexin A treatment strongly improves the response of A549/MEF tumors to doxorubicin[1]. | | IC 50 | CDK19: 0.31 μM (Kd); CDK8: 0.83 μM (Kd); CDK8: 280 nM (IC50) |
| | Senexin A Preparation Products And Raw materials |
|